|
|
Volumn 16, Issue 5, 2017, Pages 299-301
|
|
Nine paths to PCSK9 inhibition
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALIROCUMAB;
AT 04A;
AT 06A;
BMS 962476;
BMS PCKSK9RX;
DS 9001;
ENZYME ANTIBODY;
ENZYME INHIBITOR;
EVOLOCUMAB;
GLUCAGON LIKE PEPTIDE 1;
INCLISIRAN;
LONG ACTING DRUG;
MEDI 4166;
PF 06446846;
PROPROTEIN CONVERTASE 9;
SPC 5001;
UNCLASSIFIED DRUG;
VACCINE;
AUTOANTIGEN;
PCSK9 PROTEIN, HUMAN;
ARTICLE;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SAFETY;
DRUG TARGETING;
ENZYME INHIBITION;
HUMAN;
NONHUMAN;
RNAI THERAPEUTICS;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
CRISPR CAS SYSTEM;
DRUG DESIGN;
IMMUNOLOGY;
PHYSIOLOGY;
RNA INTERFERENCE;
ANIMALS;
AUTOANTIGENS;
CRISPR-CAS SYSTEMS;
DRUG DESIGN;
HUMANS;
PROPROTEIN CONVERTASE 9;
RNA INTERFERENCE;
VACCINES;
|
|
EID: 85018771284
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd.2017.83 Document Type: Article |
|
Times cited : (33)
|
|
References (0)
|
